ID | 1188 |
Name of the vaccine | Sf2aWC |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 18 to 45 years |
Description of the vaccine | Formalin-inactivated whole cell Shigella flexneri 2a killed vaccine. |
Name of the manufacturer | PATH |
Name of the manufacturing country | United States |
Year of manufacture | 2019 |
Clinical Phase status | Clinical - Withdrawn |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | Sterile liquid suspension |
Dosage | Three doses. |
Mechanism of action | IgA and IgG responses to LPS, Th1 and Th17 cytokines. |
Route of administration | Oral |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | dmLT |
Repurposing | NA |
Side effects of vaccine | Loose stools, diarrhoea, abdominal pain, bloating, defecation urgency, nausea, vomiting, headache, malaise, chills, myalgia, reactive arthritis and constipation. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 26865592 |
Clinical trial number | NCT03038243 |
Reference | NA |
Other name | NA |
Additional Links | NA
|